Fresenius Kabi expects to launch its pegfilgrastim biosimilar, Stimufend, in the EU “early next year” after revealing plans for a European Medicines Agency inspection by the end of the summer, although the US is proving a tricker prospect with COVID-19 related delays continuing to hinder US Food and Drug Administration inspections.
“We expect to launch Stimufend, first in a pre-filled syringe, followed by an on-body injector,” stated the Fresenius group’s president, CEO and chairman, Stephan Sturm,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?